LSTA Lisata Therapeutics Inc
Price (delayed)
$2.2556
Market cap
$19.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.4
Enterprise value
$3.23M
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely
Highlights
The EPS has grown by 7% YoY and by 4.4% from the previous quarter
The net income has grown by 4.1% YoY and by 3.6% from the previous quarter
LSTA's equity is down by 39% YoY and by 12% from the previous quarter
Lisata Therapeutics's quick ratio has decreased by 25% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of LSTA
Market
Valuations
Earnings
Shares outstanding
8.62M
Market cap
$19.44M
Enterprise value
$3.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
18.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.23
Revenue
$1M
Gross profit
$1M
Operating income
-$22.41M
Net income
-$19.99M
EBIT
-$20.78M
EBITDA
-$20.61M
Free cash flow
-$19.36M
Per share
Balance sheet
Liquidity
EPS
-$2.4
EPS diluted
-$2.4
Free cash flow per share
-$2.32
Book value per share
$3.52
Revenue per share
$0.12
TBVPS
$4.18
Total assets
$35M
Total liabilities
$5.69M
Debt
$0
Equity
$29.57M
Working capital
$28.97M
Debt to equity
0
Current ratio
6.16
Quick ratio
5.73
Net debt/EBITDA
0.79
Margins
Efficiency
Dividend
EBITDA margin
-2,060.9%
Gross margin
100%
Net margin
-1,998.5%
Operating margin
-2,240.9%
Return on assets
-48.7%
Return on equity
-55.3%
Return on invested capital
-145.3%
Return on capital employed
-70.7%
Return on sales
-2,078.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LSTA stock price
How has the Lisata Therapeutics stock price performed over time
Intraday
8.44%
1 week
15.59%
1 month
-5.23%
1 year
-18.86%
YTD
-24.31%
QTD
-4.02%
Financial performance
How have Lisata Therapeutics's revenue and profit performed over time
Revenue
$1M
Gross profit
$1M
Operating income
-$22.41M
Net income
-$19.99M
Gross margin
100%
Net margin
-1,998.5%
LSTA's operating income is up by 13% year-on-year and by 4.6% since the previous quarter
The net income has grown by 4.1% YoY and by 3.6% from the previous quarter
Growth
What is Lisata Therapeutics's growth rate over time
Valuation
What is Lisata Therapeutics stock price valuation
P/E
N/A
P/B
0.64
P/S
18.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.23
The EPS has grown by 7% YoY and by 4.4% from the previous quarter
LSTA's equity is down by 39% YoY and by 12% from the previous quarter
LSTA's price to book (P/B) is 9% lower than its last 4 quarters average of 0.7 but 7% higher than its 5-year quarterly average of 0.6
Efficiency
How efficient is Lisata Therapeutics business performance
The return on invested capital has dropped by 76% year-on-year and by 17% since the previous quarter
LSTA's ROE is down by 46% YoY and by 9% from the previous quarter
Lisata Therapeutics's return on assets has decreased by 41% YoY and by 8% QoQ
Dividends
What is LSTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LSTA.
Financial health
How did Lisata Therapeutics financials performed over time
The company's total assets fell by 36% YoY and by 8% QoQ
Lisata Therapeutics's quick ratio has decreased by 25% YoY and by 25% from the previous quarter
The debt is 100% less than the equity
LSTA's equity is down by 39% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.